Education
About Us
Working with TipRanks
Follow Us
Traws Pharma (TRAW)
NASDAQ:TRAW
Top Page
Traws Pharma
(NASDAQ:TRAW)
32Underperform
Traws Pharma (TRAW) vs. S&P 500 (SPY)
Market Cap
$12.08M
Dividend YieldN/A
Average Volume (3M)103.28K
Price to Earnings (P/E)―
Beta (1Y)1.49
Revenue GrowthN/A
EPS Growth-487.26%
CountryUS
Employees17
SectorHealthcare
Sector Strength72
IndustryBiotechnology
Share Statistics
EPS (TTM)-141.34
Shares Outstanding5,033,290
10 Day Avg. Volume46,914
30 Day Avg. Volume103,285
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)38.02
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$6.00Price Target Upside150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Traws Pharma Business Overview & Revenue Model
Company DescriptionTraws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
How the Company Makes MoneyTraws Pharma generates revenue primarily through the sale of its pharmaceutical products. The company's key revenue streams include direct sales to healthcare providers and distribution partnerships with healthcare organizations and pharmacies. Additionally, Traws Pharma engages in licensing agreements, allowing other companies to market its products in specific regions, which provides significant royalty income. Collaborative research and development partnerships also contribute to its earnings, as Traws Pharma often receives milestone payments and funding for joint projects. Furthermore, the company may receive government grants and incentives for its efforts in addressing rare diseases, contributing to its overall revenue.
Traws Pharma Financial Statement Overview
Summary
Traws Pharma faces significant financial challenges with minimal revenue growth, persistent operating losses, and negative equity. Despite a high gross profit margin, the negative cash flows and equity signal operational and solvency concerns. The lack of debt provides some financial flexibility, but urgent action is needed to ensure long-term sustainability.Income Statement
Traws Pharma has consistently generated minimal revenue over the years, with no growth in total revenue from 2019 to the latest TTM period. The company is operating at a loss, with negative net income and EBIT margins, indicating profitability challenges. The gross profit margin is high due to low cost of goods sold relative to revenue, but the overall financial health is concerning due to substantial operating losses.15
Very Negative
Balance Sheet
The company's balance sheet shows a troubling trend with negative stockholders' equity in the latest TTM period, indicating potential solvency issues. The absence of debt is a positive, as it reduces financial risk, but the negative equity ratio and declining assets are worrisome. Return on equity is negative, reflecting continuous losses impacting shareholders' value.20
Very Negative
Cash Flow
Cash flow analysis reveals persistent negative operating cash flow, indicating operational inefficiencies. Free cash flow has also been negative, suggesting challenges in generating cash from operations after capital expenditures. The operating cash flow to net income ratio is negative, highlighting issues in cash conversion efficiency.25
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 226.00K | 226.00K | 226.00K | 226.00K | 231.00K | 2.18M | Gross Profit |
| 214.00K | 210.00K | 212.00K | 212.00K | 231.00K | 2.18M | EBIT |
| -24.09M | -20.30M | -19.63M | -16.50M | -24.99M | -21.70M | EBITDA |
| -24.08M | -20.28M | -19.61M | -16.48M | -24.98M | -21.68M | Net Income Common Stockholders |
| -140.78M | -18.95M | -18.96M | -16.16M | -25.16M | -21.50M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 55.07M | 20.82M | 38.76M | 55.07M | 19.02M | 22.73M | Total Assets |
| 55.48M | 22.68M | 39.37M | 55.48M | 19.99M | 23.67M | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Net Debt |
| -55.07M | -20.82M | -38.76M | -55.07M | -19.02M | -22.73M | Total Liabilities |
| 9.36M | 12.01M | 11.06M | 9.36M | 13.81M | 12.10M | Stockholders Equity |
| 46.12M | 10.67M | 28.31M | 46.12M | 6.17M | 11.57M |
| Cash Flow | Free Cash Flow | ||||
| -30.18M | -17.95M | -16.29M | -19.49M | -23.09M | -20.89M | Operating Cash Flow |
| -30.18M | -17.93M | -16.29M | -19.49M | -23.07M | -20.83M | Investing Cash Flow |
| -3.65M | -14.00K | 0.00 | 0.00 | -15.00K | -55.00K | Financing Cash Flow |
| 14.00M | 0.00 | 0.00 | 55.56M | 19.36M | 26.65M |
Traws Pharma Technical Analysis
Negative
2.40
Price Trends
4.74
Negative
5.50
Negative
7.07
Negative
Market Momentum
-0.58
Negative
28.95
Positive
4.29
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TRAW, the sentiment is Negative. The current price of 2.4 is below the 20-day moving average (MA) of 2.68, below the 50-day MA of 4.74, and below the 200-day MA of 7.07, indicating a bearish trend. The MACD of -0.58 indicates Negative momentum. The RSI at 28.95 is Positive, neither overbought nor oversold. The STOCH value of 4.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TRAW.
Traws Pharma Risk Analysis
Traws Pharma disclosed 46 risk factors in its most recent earnings report. Traws Pharma reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Traws Pharma Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $394.52B | 28.28 | 20.06% | 3.03% | -4.51% | 3.69% | |
71 Outperform | $225.40B | 13.25 | 40.81% | 3.50% | 6.85% | 4577.79% | |
71 Outperform | $363.15B | 85.88 | 61.94% | 3.06% | 3.71% | -12.14% | |
68 Neutral | $142.98B | 17.89 | 9.05% | 6.70% | 8.77% | 272.80% | |
60 Neutral | $122.13B | ― | -39.10% | 4.03% | 7.32% | -214.24% | |
49 Neutral | $6.85B | 0.81 | -52.91% | 2.50% | 17.48% | 1.17% | |
32 Underperform | $12.08M | ― | -2255.45% | ― | ― | -487.26% |
* Healthcare Sector Average
Performance Comparison
TRAW
Traws Pharma
2.40
-22.60
-90.40%
BMY
Bristol-Myers Squibb
60.02
9.55
18.92%
JNJ
Johnson & Johnson
163.71
10.83
7.08%
MRK
Merck & Company
89.23
-37.99
-29.86%
PFE
Pfizer
25.21
-0.87
-3.34%
ABBV
AbbVie
205.29
30.88
17.71%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.